Role of small interfering RNA (siRNA) in targeting ocular neovascularization: A review

Supe, Shibani; Upadhya, Archana; Singh, Kavita

doi:10.1016/j.exer.2020.108329

Cited by 21 publications

(16 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Small interfering RNAs (siRNAs) are a type of non-coding, double-stranded RNA molecules with about 20-25 base pairs in length that influence mRNA gene expression. Several eye diseases have been treated with siRNAs, including retinal abnormalities, glaucoma, wound healing, and neovascularization [87]. The majority of these research used animal models, while some were evaluated in human disorders and other siRNAs still under clinical trials [88].…”

Section: Gene-based Ocular Delivery Systemsmentioning

confidence: 99%

Recent Strategies for Ocular Drug Delivery: Promises and Challenges

El-Kamel¹,

Ashour²

2023

Advanced Drug Delivery Systems

View full text Add to dashboard Cite

Ocular diseases include various anterior and posterior segment diseases. Due to the unique anatomy and physiology of the eye, efficient ocular drug delivery is a great challenge to researchers. The emerging nanoscience is playing an important role in the development of novel strategies for ocular disease management. Various active molecules have been designed to associate with nanocarriers to overcome ocular barriers and interact with certain ocular tissues. In this chapter, highlights will be made on barrier to intraocular delivery, general pathways for ocular absorption, and factors affecting intraocular bioavailability. The recent attempts of nanotechnology for treating anterior and posterior ocular diseases will be explored. This will include nanomicelles, nanoparticles, nanosuspensions, vesicular systems, in situ gel, dendrimers, contact lenses, implants, microneedles, and cell-based delivery systems. In addition, gene-based ocular delivery systems will be discussed. In this chapter, we will also provide a comprehensive overview of drug-device combinations used for ocular diseases such as glaucoma, dry eye disease, infections, and inflammations. Furthermore, drug delivery devices for ocular surgeries are discussed. Finally, challenges and future prospective of ocular delivery systems will be explored.

show abstract

Section: Gene-based Ocular Delivery Systemsmentioning

confidence: 99%

Recent Strategies for Ocular Drug Delivery: Promises and Challenges

El-Kamel¹,

Ashour²

2023

Advanced Drug Delivery Systems

View full text Add to dashboard Cite

show abstract

“…The application of miRNAs is considered more sophisticated than traditional diagnostic or therapeutic methods [ 12 ]. A previous study has shown that well-designed miRNAs which are used as therapeutic targets can provide long-term silencing in experimental studies while reducing toxicity and side effects [ 13 ]. However, the miRNA-based methods and experimental techniques face several challenges, such as low sensitivity, poor specificity, low silencing efficiency, off-target effects, and toxic reactions [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

The current landscape of microRNAs (miRNAs) in bacterial pneumonia: opportunities and challenges

2022

View full text Add to dashboard Cite

MicroRNAs (miRNAs), which were initially discovered in Caenorhabditis elegans, can regulate gene expression by recognizing cognate sequences and interfering with the transcriptional or translational machinery. The application of bioinformatics tools for structural analysis and target prediction has largely driven the investigation of certain miRNAs. Notably, it has been found that certain miRNAs which are widely involved in the inflammatory response and immune regulation are closely associated with the occurrence, development, and outcome of bacterial pneumonia. It has been shown that certain miRNA techniques can be used to identify related targets and explore associated signal transduction pathways. This enhances the understanding of bacterial pneumonia, notably for “refractory” or drug-resistant bacterial pneumonia. Although these miRNA-based methods may provide a basis for the clinical diagnosis and treatment of this disease, they still face various challenges, such as low sensitivity, poor specificity, low silencing efficiency, off-target effects, and toxic reactions. The opportunities and challenges of these methods have been completely reviewed, notably in bacterial pneumonia. With the continuous improvement of the current technology, the miRNA-based methods may surmount the aforementioned limitations, providing promising support for the clinical diagnosis and treatment of “refractory” or drug-resistant bacterial pneumonia.

show abstract

“…Recent studies have suggested that genetic and epigenetic, such as dysfunction in noncoding RNA (circRNA [ 3 ], lncRNA [ 4 ], miRNA [ 5 ], siRNA [ 6 ]), m6A mRNA methylation [ 7 ], and alternative splicing have an important role in the occurrence and progression of DR. Alternative splicing (AS) is a crucial role in various biological and pathological processes.…”

Section: Introductionmentioning

confidence: 99%

RNA-Binding Proteins and Alternative Splicing Genes Are Coregulated in Human Retinal Endothelial Cells Treated with High Glucose

Zhao

Kong

Wang

et al. 2022

Journal of Diabetes Research

View full text Add to dashboard Cite

To explore the relevant RNA-binding proteins (RBPs) and alternative splicing events (ASEs) in diabetic retinopathy (DR). We devised a comprehensive work to integrate analyses of the differentially expressed genes, including differential RBPs, and variable splicing characteristics related to DR in human retinal endothelial cells induced by low glucose and high glucose in dataset GSE117238. A total of 2320 differentially expressed genes (DEGs) were identified, including 1228 upregulated genes and 1092 downregulated genes. Further analysis screened out 232 RBP genes, and 42 AS genes overlapped DEGs. We selected high expression and consistency six RBP genes (FUS, HNRNPA2B1, CANX, EIF1, CALR, and POLR2A) for coexpression analysis. Through analysis, we found eight RASGs (MDM2, GOLGA2P7, NFE2L1, KDM4A, FAM111A, CIRBP, IDH1, and MCM7) that could be regulated by RBP. The coexpression network was conducted to further elucidate the regulatory and interaction relationship between RBPs and AS. Apoptotic progress, protein phosphorylation, and NF-kappaB cascade revealed by the functional enrichment analysis of RASGs regulated by RBPs were closely related to diabetic retinopathy. Furthermore, the expression of differentially expressed RBPs was validated by qRT-PCR in mouse retinal microvascular endothelial cells and retinas from the streptozotocin mouse model. The results showed that Fus, Hnrnpa2b1, Canx, Calr, and Polr2a were remarkedly difference in high-glucose-treated retinal microvascular endothelial cells and Fus, Hnrnpa2b1, Canx, and Calr were remarkedly difference in retinas from streptozotocin-induced diabetic mice compared to control. The regulatory network between identified RBPs and RASGs suggests the presence of several signaling pathways possibly involved in the pathogenesis of DR. The verified RBPs should be further addressed by future studies investigating associations between RBPs and the downstream of AS, as they could serve as potential biomarkers and targets for DR.

show abstract

Role of small interfering RNA (siRNA) in targeting ocular neovascularization: A review

Cited by 21 publications

References 116 publications

Recent Strategies for Ocular Drug Delivery: Promises and Challenges

Recent Strategies for Ocular Drug Delivery: Promises and Challenges

The current landscape of microRNAs (miRNAs) in bacterial pneumonia: opportunities and challenges

RNA-Binding Proteins and Alternative Splicing Genes Are Coregulated in Human Retinal Endothelial Cells Treated with High Glucose

Contact Info

Product

Resources

About